Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Revance Therapeutics Inc.

www.revance.com

Latest From Revance Therapeutics Inc.

Bookmark
  • Analysis

Good News For AbbVie: Allergan's Q2 Sales Exceed Expectations, Including Behemoth Botox

By Mandy Jackson

AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.

Sales & Earnings Business Strategies
Bookmark
  • Analysis

AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline

By Mandy Jackson

While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.

Deals Business Strategies
Bookmark
  • Analysis

Bruised Over Humira Patent Games, AbbVie Sees Smoother Road With Botox

By Cathy Kelly

AbbVie’s proposed acquisition of Allergan unites two companies that have gained notoriety for their exhaustive and unconventional efforts, respectively, to extend the patents of key products.

Pricing Strategies Intellectual Property
Bookmark
  • Analysis

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

By Mandy Jackson

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Alias(es)
  • Essentia Biosystems Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Revance Therapeutics Inc.
  • Senior Management
  • Daniel Browne, Pres. & CEO
    Tobin Schilke, CFO
    Abhay Joshi, PhD, COO
    Taryn Conway, VP, Mktg.
  • Contact Info
  • Revance Therapeutics Inc.
    Phone: (510) 742-3400
    7555 Gateway Blvd.
    Newark, CA 94560
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By